HIPRA - About the company
HIPRA is a funded company based in Amer (Spain), founded in 1996. It operates as a Developer of vaccines and diagnostic kit for animals. HIPRA has raised an undisclosed amount in funding. The company has 432 active competitors, including 112 funded and 94 that have exited. Its top competitors include companies like Dynavax, HOOKIPA Pharma and Atea.
Company Details
HIPRA develops vaccines and diagnostic kits for animals. The company provides vaccines for diseases like viral nervous necrosis, bursal disease, respiratory syncytial virus, and others. The company provides detection and quantification kits for diseases like mycoplasma hyopneumoniae, Leishmania donovani infantum, and others.
- Website
- hipra.com/en
- Email ID
- *****@hipra.com
- Phone Number
- +34 **********
- Registered Address
- 7, Ådalen, Vejen, 6600
Key Metrics
Founded Year
1996
Location
Amer, Spain
Stage
Funding Raised
Latest Funding Round
Investors
Ranked
119th among 432 active competitors
Employee Count
2,087 as on Apr 30, 2026
Investment & Acquisitions
Similar Companies
Legal entities associated with HIPRA
HIPRA is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
HIPRA NORDIC ApS CIN: 35407464 , Denmark, Active | Jul 24, 2013 | - | 8 (As on Aug 31, 2024) |
Sign up to download HIPRA's company profile
HIPRA's funding and investors
HIPRA has raised funding over 1 round. Its latest funding round was a Grant (prize money) round on Dec 01, 2021 for $*****. 1 investor participated in its latest round. HIPRA has 1 institutional investor.
Here is the list of recent funding rounds of HIPRA:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Dec 01, 2021 | 2961190 | Grant (prize money) | 3814694 | 7541309 | 7874673 | 3699363 |
Access funding benchmarks and valuations. Sign up today!View details of HIPRA's funding rounds and investors
HIPRA's founders and board of directors
Founder? Claim ProfileHIPRA's employee count trend
HIPRA has 2,087 employees as of Apr 26. Here is HIPRA's employee count trend over the years:
Uncover HIPRA's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
HIPRA's Competitors and alternates
Top competitors of HIPRA include Dynavax, HOOKIPA Pharma and Atea. Here is the list of Top 10 competitors of HIPRA, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Dynavax 1996, Berkeley (United States), Acquired | Developer of products to prevent and treat infectious and inflammatory diseases and cancer | $73.9M | 72/100 | |
2nd |  HOOKIPA Pharma 2011, Vienna (Austria), Public | Developer of immunotherapies for the treatment of infectious diseases and cancer | $134M | 68/100 | |
3rd | _1579497693661.png?devicePixelRatio=2&height=30&width=30){kind=logo} Atea 2014, Boston (United States), Public | Developer of therapeutics for viral diseases | $293M | 67/100 | |
4th |  Generate Biomedicines 2018, Somerville (United States), Public | Developer of a platform for generating novel protein-based therapeutic modalities | $693M | 66/100 | |
5th |  Leyden Labs 2020, Amsterdam (Netherlands), Series B | Developer of nasal sprays containing antibodies targeting respiratory viruses in the nasal mucosa | $257M | 64/100 | |
6th | Alchemab 2019, London (United Kingdom), Series A | Developer of antibody based therapeutics to treat cancers, neurodegenerative conditions and infectious diseases | $115M | 64/100 | |
7th |  Brii Biosciences 2018, San Francisco (United States), Public | Developer of biologics to treat hepatitis B infection | $415M | 63/100 | |
8th | Visterra 2007, Cambridge (United States), Acquired | Developer of monoclonal antibodies against infectious diseases | $116M | 62/100 | |
9th | VBI Vaccines 2001, Cambridge (United States), Public | Developer of vaccines for the treatment of infectious diseases | $65.1M | 62/100 | |
10th | Developer of vaccines against multiple infectious diseases | - | 62/100 | ||
119th | Developer of vaccines and diagnostic kit for animals | - | 46/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on HIPRA's competitors? Click here to see the top ones
HIPRA's Investments and acquisitions
HIPRA has acquired GoodGut. HIPRA has not made any investments as of now.Reports related to HIPRA
Here is the latest report on HIPRA's sector:
News related to HIPRA
Filter this listMedia has covered HIPRA for a total of 4 events in the last 1 year, 1 of them has been about company updates and 1 about people movement.
•
Catalonia Hipra signs former Werfen and Novartis executives as independent directorsExpansion•Dec 17, 2025•HIPRA, Werfen
•
•
•
•
•
HIPRA launches CDMO unit for biologic drug development and manufacturing.Pharmatech•Jan 22, 2025•HIPRA
•
•
•
•
Veristat Congratulates HIPRA on EMA Approval of its BIMERVAX® COVID-19 VaccineBusiness Wire•Apr 25, 2023•Veristat, HIPRA
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about HIPRA
Explore our recently published companies
- Scylos - Nashville based, 2025 founded, Seed company
- Techhive Technologies - Ikeja based, 2017 founded, Unfunded company
- Neumann Systems Group - Colorado Springs based, 2021 founded, Funding Raised company
- Orphi-tx.com - Funding Raised company
- H2Pump - Latham based, 2005 founded, Funding Raised company
- Bloom Pickleball - San Francisco based, 2011 founded, Funding Raised company
